Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Roche Holding Ag (RO.SW)
Roche Wins CE Mark For Elecsys ApoE4 Blood Test To Detect Alzheimer's Disease Risk Variant
3/16/2026 2:23:25 AM
Roche Gains CE Mark For Elecsys ApoE4 Blood Test, First IVD To Detect Alzheimer’s Risk Variant
3/16/2026 2:07:33 AM
Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired
3/13/2026 10:14:13 AM
Roche Shareholders Approve All Proposals At 2026 Annual Meeting
3/10/2026 10:43:06 AM
Roche Says Shareholders Approved All Proposals Of Board; Severin Schwan Re-elected As Chairman
3/10/2026 9:30:37 AM
Genentech: PersevERA Breast Cancer Study Fails To Meet Primary Objective
3/9/2026 2:46:04 AM
Genentech’s Phase III Trial Of Giredestrant Combo In ER+/HER2- Breast Cancer Misses Primary Endpoint
3/9/2026 2:16:24 AM
Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet
3/6/2026 9:50:41 AM
Genentech Says Phase 3 ALLEGORY Study Of Gazyva In SLE Published In New England Journal Of Medicine
3/6/2026 9:08:25 AM
Genentech’s Phase III ALLEGORY Trial Of Gazyva In SLE Published In NEJM, Shows Significant Clinical Benefit
3/6/2026 8:48:55 AM
Roche's Petrelintide Achieves Over 100% Weight Loss In Phase 2 Trial
3/5/2026 9:38:51 PM
Roche's Phase III Study Of Fenebrutinib Meets Primary Endpoint In Relapsing Multiple Sclerosis
3/2/2026 1:30:47 AM
Roche : Fenebrutinib Phase III Trial Meets Primary Endpoint In Relapsing Multiple Sclerosis
3/2/2026 1:13:20 AM
Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020
2/20/2026 9:27:44 AM
FDA Approves Genentech's Venclexta And Acalabrutinib Combo For Untreated CLL
2/20/2026 2:27:34 AM
Roche Announces Filing Acceptance Of New Drug Application For Giredestrant
2/20/2026 1:36:16 AM
Genentech: FDA Accepts Giredestrant NDA In ESR1-Mutated, ER-Positive Advanced Breast Cancer
2/20/2026 1:16:27 AM
Roche Names Mark Dawson New Head Of Roche Pharma Research And Early Development, Effective May 1
2/17/2026 1:17:32 AM
Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy
2/16/2026 1:43:11 AM
Genentech’s Phase III MAJESTY Trial Shows Gazyva Outperforms Tacrolimus In Primary Membranous Nephropathy
2/16/2026 1:06:02 AM
«
Previous
1
2
3
Next
»